To date, therapeutic NCD vaccines that have been approved for clinical use include CimaVax-EGF (for non-small cell lung cancer), Sipuleucel-T (for prostate cancer), and Inclisiran (for dsylipidemia). This evidence concerns the gene EGF and non-small cell lung carcinoma.